RYAN Stock Analysis: Ryan Specialty Holdings | NYSE
Insurance - Specialty | NYSE, USA | Market Cap: 16.310m USD | 12M Return: -27.8% | US78351F1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 90.1M
EPS Trend: 97.6%
Qual. Beats: 2
Rev. Trend: 99.6%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ryan Specialty Group Holdings, Inc. (NYSE: RYAN) is a Chicago-headquartered specialty insurance services provider founded in 2010 and listed on the NYSE following its July 2021 IPO. Operating in the U.S., Canada, the U.K., broader Europe, India, Singapore, and other international markets, the company serves insurance brokers, agents, and carriers across commercial, industrial, institutional, individual, and government sectors. Its offerings span distribution, underwriting, product development, administration, and risk management, delivered through two primary roles: wholesale brokerage and managing underwriting/program administration with delegated authority from insurance carriers. As a wholesale broker and managing general underwriter, Ryan Specialty sits between retail brokers and carriers, focusing on complex and niche risks that are typically underwritten outside of standard direct channels, which is consistent with the GICS Insurance Brokers sub-industry classification.
- E&S market share gains drive double-digit organic growth
- Acquisition pipeline adds new wholesale brokerage capabilities
- Hard market pricing cycle boosts commission and fee income
| Net Income: 188.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.61 > 1.0 |
| NWC/Revenue: 36.88% < 20% (prev 164.8%; Δ -127.9% < -1%) |
| CFO/TA 0.05 > 3% & CFO 558.5m > Net Income 188.0m |
| Net Debt (3.84b) to EBITDA (789.7m): 4.86 < 3 |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (131.3m) vs 12m ago -52.10% < -2% |
| Gross Margin: 81.13% > 18% (prev 40.27%; Δ 40.87% > 0.5%) |
| Asset Turnover: 28.48% > 50% (prev 26.48%; Δ 2.01% > 0%) |
| Interest Coverage Ratio: 2.29 > 6 (EBIT TTM 504.5m / Interest Expense TTM 219.9m) |
| A: 0.10 (Total Current Assets 6.64b - Total Current Liabilities 5.46b) / Total Assets 12.0b |
| B: 0.01 (Retained Earnings 145.3m / Total Assets 12.0b) |
| C: 0.04 (EBIT TTM 504.5m / Avg Total Assets 11.3b) |
| D: 0.05 (Book Value of Equity 509.4m / Total Liabilities 11.0b) |
| Altman-Z'' = 1.04 = BB |
| DSRI: 0.12 (Receivables 697.6m/5.03b, Revenue 3.22b/2.81b) |
| GMI: 0.50 (GM 40.27% / 81.13%) |
| AQI: 0.89 (AQ_t 0.43 / AQ_t-1 0.48) |
| SGI: 1.14 (Revenue 3.22b / 2.81b) |
| TATA: -0.03 (NI 188.0m - CFO 558.5m) / TA 12.0b) |
| Beneish M = -4.17 (Cap -4..+1) = AAA |
As of August 20, 2026, the stock is trading at USD 42.21 with a total of 933,360 shares traded. Over the past week, the price has changed by -1.54%, over one month by +0.88%, over three months by +25.38% and over the past year by -27.79%.
Current recommended Stop Loss: 39.90 (which is 5.5% or 1.3 ATR below the current price).
Ryan Specialty Holdings has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy RYAN.
- StrongBuy: 4
- Buy: 5
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 50.3 | 19.3% |
P/E Trailing = 56.5135
P/E Forward = 21.7865
P/S = 5.1561
P/B = 21.0009
Revenue TTM = 3.22b USD
EBIT TTM = 504.5m USD
EBITDA TTM = 789.7m USD
Long Term Debt = 3.57b USD (from longTermDebt, last quarter)
Short Term Debt = 90.4m USD (from shortTermDebt, last quarter)
Debt = 3.98b USD (from shortLongTermDebtTotal, last quarter) + Leases 174.4m
Net Debt = 3.84b USD (calculated: Debt 3.98b - CCE 140.1m)
Enterprise Value = 20.2b USD (16.3b + Debt 3.98b - CCE 140.1m)
Interest Coverage Ratio = 2.29 (Ebit TTM 504.5m / Interest Expense TTM 219.9m)
EV/FCF = 39.19x (Enterprise Value 20.2b / FCF TTM 514.2m)
FCF Yield = 2.55% (FCF TTM 514.2m / Enterprise Value 20.2b)
FCF Margin = 15.98% (FCF TTM 514.2m / Revenue TTM 3.22b)
Net Margin = 5.84% (Net Income TTM 188.0m / Revenue TTM 3.22b)
Gross Margin = 81.13% ((Revenue TTM 3.22b - Cost of Revenue TTM 607.1m) / Revenue TTM)
Gross Margin QoQ = 92.52% (prev 91.27%)
Tobins Q-Ratio = 1.68 (Enterprise Value 20.2b / Total Assets 12.0b)
Interest Expense / Debt = 5.52% (Interest Expense 219.9m / Debt 3.98b)
Taxrate = 13.97% (39.4m / 282.2m)
NOPAT = 434.0m (EBIT 504.5m * (1 - 13.97%))
Current Ratio = 1.15 (Total Current Assets 6.64b / Total Current Liabilities 5.80b)
Debt / Equity = 7.82 (Debt 3.98b / totalStockholderEquity, last quarter 509.4m)
Debt / EBITDA = 4.86 (Net Debt 3.84b / EBITDA 789.7m)
Debt / FCF = 7.47 (Net Debt 3.84b / FCF TTM 514.2m)
Total Stockholder Equity = 606.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.66% (Net Income 188.0m / Total Assets 12.0b)
RoE = 31.03% (Net Income TTM 188.0m / Total Stockholder Equity 606.0m)
RoCE = 12.08% (EBIT 504.5m / Capital Employed (Equity 606.0m + L.T.Debt 3.57b))
RoIC = 3.67% (NOPAT 434.0m / Invested Capital 11.8b)
WACC = 5.16% (E(16.3b)/V(20.3b) * Re(5.26%) + D(3.98b)/V(20.3b) * Rd(5.52%) * (1-Tc(0.14)))
Discount Rate = 5.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -54.49 | Cagr: -27.40%
[DCF] Terminal Value 77.97% ; FCFF base≈465.3m ; Y1≈533.4m ; Y5≈785.0m
[DCF] Fair Price = 65.30 (EV 11.8b - Net Debt 3.84b = Equity 7.97b / Shares 122.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.57 | EPS CAGR: 19.06% | SUE: 4.0 | # QB: 2
Revenue Correlation: 99.63 | Revenue CAGR: 20.51% | SUE: 2.91 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=-3.60% | Revisions=+42% | Analysts=18
EPS current Year (2026-12-31): EPS=2.16 | Chg30d=+5.28% | Revisions=+32% | GrowthEPS=+10.4% | GrowthRev=+7.8%
EPS next Year (2027-12-31): EPS=2.41 | Chg30d=+2.57% | Revisions=+39% | GrowthEPS=+11.4% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: +42% (up=29, down=11)